Entrada reports Q2 2026 results with DMD data due by year-end, VX-670 update ahead

Entrada Therapeutics reported second quarter 2026 financial results and business updates on August 5, 2026. Enrollment is complete for Cohort 2 of the global Phase 1/2 multiple ascending dose portion of the ELEVATE-44-201 study of ENTR-601-44 in ambulatory participants living with DMD amenable to exon 44 skipping.¹ Previously announced Cohort 1 data met the primary objective of favorable safety and tolerability, with no discontinuations and no serious adverse events, and showed early functional benefits in Time to Rise and Time to Rise velocity versus placebo.¹ The company expects to report data from the Cohort 1 open-label period (6 mg/kg) by year-end 2026, with Cohort 2 MAD (12 mg/kg) data expected in the first quarter of 2027.¹

For ENTR-601-45, the company completed enrollment and dosing of Cohort 1 of the ELEVATE-45-201 study, and an independent Data Monitoring Committee recommended initiation of Cohort 2 at an increased dose of 10 mg/kg without protocol modification.¹ Cohort 2 dosing at 10 mg/kg is ongoing, with Cohort 1 (5 mg/kg) data expected in October 2026 and Cohort 2 (10 mg/kg) data expected in the first half of 2027.¹

On regulatory steps, Entrada received authorization from the U.K.'s MHRA and a Research Ethics Committee to initiate a Phase 1/2 MAD study of ENTR-601-50 in patients amenable to exon 50 skipping.¹ It also completed Clinical Trial Authorization-enabling studies for ENTR-601-51, targeting the largest exon-skipping amenable sub-population.¹

On the partnered DM1 program, Vertex has completed enrollment and continues dosing in the MAD portion of the GALILEO Phase 1/2 trial of VX-670, and is on track to complete dosing and report results in the second half of 2026.¹

Financially, cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, down from $295.7 million as of December 31, 2025.¹ The company said this is expected to fund operations into the third quarter of 2027.¹ Net loss was $42.8 million for the quarter, compared with $43.1 million a year earlier.¹